Taiwan-based biopharmaceutical company PharmaEngine, Inc. announced its financial results for 2024, reporting a net profit of NT$1.75 billion—a remarkable 530% year-over-year increase. Earnings per share (EPS) reached NT$12.19 for the year. The company's fourth-quarter performance was particularly strong, with net earnings of NT$1.418 billion, reflecting a 1,430% quarter-over-quarter growth and an EPS of NT$9.87, making it the most profitable quarter of the year.

Dividend Announcement and Financial Highlights PharmaEngine's board of directors has approved a cash dividend of NT$6 per share. Based on the company's closing stock price of NT$113 on the previous trading day, the dividend yield stands at 5.3%, reinforcing investor confidence in the company’s financial health and growth prospects.

Milestone Revenue Boost from ONIVYDE® Sales The substantial increase in PharmaEngine’s fourth-quarter earnings was primarily driven by the sales performance of ONIVYDE® (nanoliposomal irinotecan), an innovative treatment for pancreatic cancer. The company received a US$50 million milestone payment after ONIVYDE® achieved its second-tier sales milestone in the Europe and Asia (EU/Asia) markets in 2023. This significant revenue contribution underscores the drug’s growing adoption and market penetration in these regions.

Revised Revenue Figures for December and Full-Year 2023 PharmaEngine also announced a revision to its previously reported revenue figures. Initially, the company reported December 2023 revenue at NT$150 million, with full-year revenue at NT$845 million. However, following adjustments, the updated figures reflect a substantial increase, with December revenue reaching NT$1.833 billion and full-year revenue climbing to NT$2.523 billion.

With continued expansion in the global oncology market and a strong financial position, PharmaEngine is well-positioned for sustained growth, leveraging ONIVYDE®’s success and ongoing developments in its oncology pipeline.

Resource: 智擎2024年EPS 12.19元 里程碑金進補